Archives

Intelligent Medical Objects Announces the Acquisition of Melax Technologies Inc.

Intelligent Medical

Intelligent Medical Objects (IMO), a leading provider of clinical terminology management and data quality solutions for healthcare, announced that it has acquired Melax Technologies, Inc. (Melax Tech). Melax Tech empowers the healthcare and life sciences industries through use of Artificial Intelligence (AI) and Natural Language Processing (NLP) technologies to extract information from biomedical textual data to solve real-world problems. The acquisition of Melax Tech will enhance IMO’s portfolio of healthcare data solutions and enable IMO to expand its offerings to various segments in the healthcare market to tackle diverse problems like improving clinical and administrative workflows, clinical research, and patient outcomes.

“Combining Melax Tech’s analytics and NLP capabilities with IMO’s clinical terminology and data quality platform will enable healthcare organizations to have a more comprehensive solution for both clinical operation and research. The acquisition will also help extend our state-of-the-art capabilities to payer, pharmaceutical, and life science companies.”

“ Marks an exciting moment for Intelligent Medical Objects IMO as we complete our first acquisition,” said Ann Barnes, Chief Executive Officer at IMO. “Combining Melax Tech’s analytics and NLP capabilities with IMO’s clinical terminology and data quality platform will enable healthcare organizations to have a more comprehensive solution for both clinical operation and research. The acquisition will also help extend our state-of-the-art capabilities to payer, pharmaceutical, and life science companies.”

Also Read: Abbott Unveils Late-Breaking Data Showing the World’s First Dual-Chamber Leadless Pacemaker Study Met All Three Primary Endpoints 

For nearly 30 years, IMO solutions have helped physicians document in their own words while capturing the right codes behind the scenes. IMO is the clinical terminology foundation in all major EHRs and 89% of US clinicians use IMO solutions. IMO is the catalyst that enables accurate documentation, precise population cohorting, optimized reimbursements, robust analytics, and better care decisions to optimize patient outcomes.

Melax Tech is trusted by 650+ leading organizations for a variety of use cases, including advanced applications for cohort discovery, clinical trials optimization, and knowledge integration.

“We are thrilled to join forces with IMO and combine our NLP expertise with their clinical terminology and knowledge management solutions,” said Andre Pontin, CEO of Melax Tech. “Together, we will be able to offer healthcare organizations a powerful suite of solutions that will enable them to improve patient outcomes and reduce costs.”

SOURCE: Businesswire